Search

Tests of microfiltration efficiency used for the pretreatment of backwash water from sand filters were conducted at two water treatment plants treating surface water and infiltration water. Microfiltration efficiency was evaluated for three membrane modules: two with polymeric membranes and one with a ceramic membrane. This study showed that the contaminants that limit the reuse of backwash water from both plants by returning them to the water treatment line are mostly microorganisms, including pathogenic species ( Clostridium perfringens ). Additionally, in the case of backwash water from infiltration water treatment, iron and manganese compounds also had to be removed before its recirculation to the water treatment system. Unexpectedly, organic carbon concentrations in both types of backwash water were similar to those present in intake waters. Microfiltration provided for the removal of organic matter, ranging from 19.9% to 44.5% and from 7.2% to 53.9% for backwash water from the treatments of surface water and infiltration water, respectively. Furthermore, the efficiency of the iron removal from backwash water from infiltration water treatment was sufficient to ensure good intake water quality. On the other hand, manganese concentrations in the backwash water, from infiltration water treatment, pretreated using the microfiltration process exceeded the levels found in the intake water and were, therefore, an additional limiting factor for the reuse of the backwash water. In both types of backwash water, the number of microorganisms, including Clostridium perfringens (a pathogenic one), was a limiting parameter for backwash water reuse without pretreatment. The results of the present study showed the possibility for using microfiltration for the pretreatment of backwash water, regardless of its origin but not as the sole process. More complex technological systems are needed before recirculating backwash water into the water treatment system. The polyvinylidene fluoride (PVDF) membrane proved to be the most effective for DOC and microorganism removal from backwash water.

Background: Pulmonary hypertension (PH) can cause right ventricular (RV) failure and subsequent cardiohepatic syndrome referred to as congestive hepatopathy (CH). Passive blood stasis in the liver can affect inflammation, fibrosis, and ultimately cirrhosis. Cannabidiol (CBD) has many beneficial properties including anti-inflammatory and reduces RV systolic pressure and RV hypertrophy in monocrotaline (MCT)-induced PH in rats. Thus, it suggests that CBD may have the potential to limit CH development secondary to RV failure. The present study aimed to determine whether chronic administration of CBD can inhibit the CH secondary to RV hypertrophy associated with MCT-induced PH., Methods: The experiments involved rats with and without MCT-induced PH. CBD (10 mg/kg) or its vehicle was administered once daily for 3 weeks after MCT injection (60 mg/kg)., Results: Monocrotaline administration increased the liver/body weight ratio. In histology examinations, we observed necrosis and vacuolar degeneration of hepatocytes as well as sinusoidal congestion. In biochemical studies, we observed increased levels of nuclear factor-κappa B (NF-κB), tumour necrosis factor-alpha (TNA-α), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6). CBD administration to PH rats reduced the liver/body weight ratio, improved the architecture of the liver, and inhibited the formation of necrosis. Cannabidiol also decreased the level of NF-κB, TNF-α, IL-1β and IL-6., Conclusions: The studies show that CBD can protect the liver from CH probably through attenuating PH, protective effects on the RV, and possibly direct anti-inflammatory effects on liver tissue through regulation of the NF-κB pathway., (© 2024. The Author(s).)